TransMedics Group (NASDAQ:TMDX) Raised to “Strong-Buy” at Baird R W

Baird R W upgraded shares of TransMedics Group (NASDAQ:TMDX) to a strong-buy rating in a research note released on Tuesday, Zacks.com reports.

Several other research analysts also recently weighed in on the company. Stephens lifted their target price on TransMedics Group from $151.00 to $178.00 and gave the company an overweight rating in a research note on Friday, August 2nd. Canaccord Genuity Group lifted their target price on TransMedics Group from $117.00 to $169.00 and gave the company a buy rating in a research note on Thursday, August 1st. Robert W. Baird initiated coverage on TransMedics Group in a research note on Tuesday. They issued an outperform rating and a $200.00 target price on the stock. TD Cowen raised their price target on TransMedics Group from $130.00 to $175.00 and gave the company a buy rating in a report on Friday, June 7th. Finally, Cantor Fitzgerald initiated coverage on TransMedics Group in a report on Thursday, June 6th. They issued an overweight rating and a $161.00 price target for the company. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Buy and an average target price of $174.30.

TransMedics Group Trading Down 2.5 %

NASDAQ:TMDX opened at $144.56 on Tuesday. The stock’s 50 day moving average price is $156.02 and its 200 day moving average price is $130.77. The company has a market capitalization of $4.82 billion, a PE ratio of -425.18 and a beta of 1.99. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. TransMedics Group has a 52-week low of $36.42 and a 52-week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The firm had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The firm’s quarterly revenue was up 117.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.03) EPS. On average, research analysts anticipate that TransMedics Group will post 1.23 EPS for the current year.

Insiders Place Their Bets

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $149.96, for a total value of $1,012,230.00. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at $109,770.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 61,247 shares of company stock valued at $9,650,880. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently made changes to their positions in TMDX. Principal Financial Group Inc. grew its position in shares of TransMedics Group by 21.3% in the fourth quarter. Principal Financial Group Inc. now owns 21,929 shares of the company’s stock valued at $1,731,000 after purchasing an additional 3,858 shares during the period. Hsbc Holdings PLC grew its position in shares of TransMedics Group by 19.0% in the fourth quarter. Hsbc Holdings PLC now owns 41,650 shares of the company’s stock valued at $3,287,000 after purchasing an additional 6,650 shares during the period. Alpha DNA Investment Management LLC purchased a new stake in shares of TransMedics Group in the fourth quarter valued at $500,000. First Light Asset Management LLC grew its position in shares of TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after purchasing an additional 136,217 shares during the period. Finally, Osterweis Capital Management Inc. grew its position in shares of TransMedics Group by 78.5% in the fourth quarter. Osterweis Capital Management Inc. now owns 64,565 shares of the company’s stock valued at $5,096,000 after purchasing an additional 28,390 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.